A Nano-Interception Strategy for Chronic Heart Failure: Prussian Blue Nanoparticles Disrupt Fibroblast-Immune...

Area of Science:

• Nanomedicine
• Cardiovascular Research
• Immunology

Background:

• Chronic heart failure (HF) lacks therapies targeting disease-driving fibro-inflammatory networks.
• Current nanomedicine often misses crucial multicellular communication in HF.

Purpose of the Study:

• Develop novel Prussian blue (PB) nanoparticles to disrupt intercellular communication in HF.
• Target the CCL2-CCR2 chemokine axis, vital for fibroblast-macrophage interactions.

Main Methods:

• Synthesized scalable Prussian blue nanoparticles.
• Utilized single-nucleus RNA sequencing to identify cardiac fibroblast subpopulations.
• Assessed nanoparticle efficacy in murine and porcine pressure-overload HF models.

Main Results:

• PB nanoparticles selectively bind CCL2, blocking its interaction with CCR2.
• Demonstrated significant improvement in cardiac function and reduced fibrosis in HF models.
• Achieved selective depletion of CCR2+ macrophages without systemic immunosuppression.

Conclusions:

• Established a novel nanomedicine strategy targeting cell communication networks for HF treatment.
• PB nanoparticles show potential for scalable, stable, and safe therapeutic application.
• This approach offers a new paradigm for treating network-driven diseases like HF.